Verus Capital Partners’s Allergan plc AGN Stock Holding History

Verus Capital Partners’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3	Closed	-$1K	–	1645
2019 Q4	$1K	Buy	+3	New	+$541	﹤0.01%	1515

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Verus Capital Partners's AGN Position: Q1 2020 in Review

Verus Capital Partners sold out of Allergan plc (AGN) in Q1 2020, closing a stake of 3 shares — an estimated $1K sold.

Verus Capital Partners first reported a position in AGN in Q4 2019 and held it in 1 quarter. The position peaked at $1K in Q4 2019. 876 funds tracked by Wall St. Rank hold AGN as of Q1 2020.

Verus Capital Partners reported no remaining Allergan plc position as of Q1 2020 after selling out during the quarter.
Verus Capital Partners sold 3 Allergan plc shares in Q1 2020, an estimated $1K.
Verus Capital Partners first reported a position in Allergan plc in Q4 2019 and held it in 1 quarter.
Verus Capital Partners's Allergan plc position peaked at $1K in Q4 2019.
876 funds tracked by Wall St. Rank held Allergan plc as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.